Cargando…

Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling

Levonorgestrel (LNG) is the active moiety in many hormonal contraceptive formulations. It is typically coformulated with ethinyl estradiol (EE) to decrease intermenstrual bleeding. Due to its widespread use and CYP3A4‐mediated metabolism, there is concern regarding drug‐drug interactions (DDIs), par...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicali, Brian, Lingineni, Karthik, Cristofoletti, Rodrigo, Wendl, Thomas, Hoechel, Joachim, Wiesinger, Herbert, Chaturvedula, Ayyappa, Vozmediano, Valvanera, Schmidt, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825189/
https://www.ncbi.nlm.nih.gov/pubmed/33217171
http://dx.doi.org/10.1002/psp4.12572
_version_ 1783640250634993664
author Cicali, Brian
Lingineni, Karthik
Cristofoletti, Rodrigo
Wendl, Thomas
Hoechel, Joachim
Wiesinger, Herbert
Chaturvedula, Ayyappa
Vozmediano, Valvanera
Schmidt, Stephan
author_facet Cicali, Brian
Lingineni, Karthik
Cristofoletti, Rodrigo
Wendl, Thomas
Hoechel, Joachim
Wiesinger, Herbert
Chaturvedula, Ayyappa
Vozmediano, Valvanera
Schmidt, Stephan
author_sort Cicali, Brian
collection PubMed
description Levonorgestrel (LNG) is the active moiety in many hormonal contraceptive formulations. It is typically coformulated with ethinyl estradiol (EE) to decrease intermenstrual bleeding. Due to its widespread use and CYP3A4‐mediated metabolism, there is concern regarding drug‐drug interactions (DDIs), particularly a suboptimal LNG exposure when co‐administered with CYP3A4 inducers, potentially leading to unintended pregnancies. The goal of this analysis was to determine the impact of DDIs on the systemic exposure of LNG. To this end, we developed and verified a physiologically‐based pharmacokinetic (PBPK) model for LNG in PK‐Sim (version 8.0) accounting for the impact of EE and body mass index (BMI) on LNG’s binding to sex‐hormone binding globulin. Model parameters were optimized following intravenous and oral administration of 0.09 mg LNG. The combined LNG‐EE PBPK model was verified regarding CYP3A4‐mediated interaction by comparing to published clinical DDI study data with carbamazepine, rifampicin, and efavirenz (CYP3A4 inducers). Once verified, the model was applied to predict systemic LNG exposure in normal BMI and obese women (BMI ≥ 30 kg/m(2)) with and without co‐administration of itraconazole (competitive CYP3A4 inhibitor) and clarithromycin (mechanism‐based CYP3A4 inhibitor). Total and free LNG exposures, when co‐administered with EE, decreased 2‐fold in the presence of rifampin, whereas they increased 1.5‐fold in the presence of itraconazole. Although changes in total and unbound exposure were decreased in obese women compared with normal BMI women, the relative impact of DDIs on LNG exposure was similar between both groups.
format Online
Article
Text
id pubmed-7825189
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78251892021-02-01 Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling Cicali, Brian Lingineni, Karthik Cristofoletti, Rodrigo Wendl, Thomas Hoechel, Joachim Wiesinger, Herbert Chaturvedula, Ayyappa Vozmediano, Valvanera Schmidt, Stephan CPT Pharmacometrics Syst Pharmacol Research Levonorgestrel (LNG) is the active moiety in many hormonal contraceptive formulations. It is typically coformulated with ethinyl estradiol (EE) to decrease intermenstrual bleeding. Due to its widespread use and CYP3A4‐mediated metabolism, there is concern regarding drug‐drug interactions (DDIs), particularly a suboptimal LNG exposure when co‐administered with CYP3A4 inducers, potentially leading to unintended pregnancies. The goal of this analysis was to determine the impact of DDIs on the systemic exposure of LNG. To this end, we developed and verified a physiologically‐based pharmacokinetic (PBPK) model for LNG in PK‐Sim (version 8.0) accounting for the impact of EE and body mass index (BMI) on LNG’s binding to sex‐hormone binding globulin. Model parameters were optimized following intravenous and oral administration of 0.09 mg LNG. The combined LNG‐EE PBPK model was verified regarding CYP3A4‐mediated interaction by comparing to published clinical DDI study data with carbamazepine, rifampicin, and efavirenz (CYP3A4 inducers). Once verified, the model was applied to predict systemic LNG exposure in normal BMI and obese women (BMI ≥ 30 kg/m(2)) with and without co‐administration of itraconazole (competitive CYP3A4 inhibitor) and clarithromycin (mechanism‐based CYP3A4 inhibitor). Total and free LNG exposures, when co‐administered with EE, decreased 2‐fold in the presence of rifampin, whereas they increased 1.5‐fold in the presence of itraconazole. Although changes in total and unbound exposure were decreased in obese women compared with normal BMI women, the relative impact of DDIs on LNG exposure was similar between both groups. John Wiley and Sons Inc. 2020-12-13 2021-01 /pmc/articles/PMC7825189/ /pubmed/33217171 http://dx.doi.org/10.1002/psp4.12572 Text en © 2020 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Cicali, Brian
Lingineni, Karthik
Cristofoletti, Rodrigo
Wendl, Thomas
Hoechel, Joachim
Wiesinger, Herbert
Chaturvedula, Ayyappa
Vozmediano, Valvanera
Schmidt, Stephan
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
title Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
title_full Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
title_fullStr Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
title_full_unstemmed Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
title_short Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
title_sort quantitative assessment of levonorgestrel binding partner interplay and drug‐drug interactions using physiologically based pharmacokinetic modeling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825189/
https://www.ncbi.nlm.nih.gov/pubmed/33217171
http://dx.doi.org/10.1002/psp4.12572
work_keys_str_mv AT cicalibrian quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT linginenikarthik quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT cristofolettirodrigo quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT wendlthomas quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT hoecheljoachim quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT wiesingerherbert quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT chaturvedulaayyappa quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT vozmedianovalvanera quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling
AT schmidtstephan quantitativeassessmentoflevonorgestrelbindingpartnerinterplayanddrugdruginteractionsusingphysiologicallybasedpharmacokineticmodeling